Introduction
actin cytoskeleton (i.e. stress fibre formation). All of these events have been associated with the increased endothelial permeability induced by VCAM-1 cross-linking [11] .
We hypothesized that inactivation of VCAM-1 via transfection of genes encoding for fusion proteins that compete with VCAM-1's cytoskeletal anchorage reduces monocyte adhesion to endothelial cells. However, the interaction of VCAM-1 with the cytoskeleton has not been studied very well and tools to study these interactions are not readily available. In contrast to this, in another family of adhesion molecules, the integrins, the interaction with the cytoskeleton has been well described and proven tools to study this interaction are available [12] . Particularly for the platelet integrin ␣IIb␤3 (CD41/CD61) the interaction with the cytoskeleton has been well characterized and we have previously visualized this interaction with immunofluorescence microscopy in the form of adhesion plaque and actin stress fibre formation [13] [14] [15] [16] . Since [17, 18] . Very recently, the adenoviral delivery of gene vectors was combined with the local delivery via a biodegradable coating of stents [19] . This approach was used to prevent restenosis after stenting of atherosclerotic plaques [19] . Overall, besides the local injection into the coronary arteries, stent-associated delivery may also be useful in general to deliver therapeutic genes with anti-atherosclerotic effects in interventional cardiology. [20] and cloned into pUHD10-3 (Manfred Gossen, ZMBH, Heidelberg) (Fig. 1) 
VCAM-1 does not localize to adhesion plaques and does not mediate typical stress fibre formation, the visualization of its cytoskeletal interaction is not possible by immunofluorescence micropscopy. Therefore, we used the interaction of the integrin ␣IIb␤3 with the cytoskeleton as a pilot experimental setup and in a second step we then transferred the outcome of this pilot study to an approach aiming at the targeted interruption of VCAM-1's cytoskeletal anchorage. In order to interfere with ␣IIb␤3 cytoskeletal anchorage, we developed different fusion molecules composed of the intracellular part of ␤3 and the extracellular and transmembrane part of CD7 as an inert marker. As a proof of concept, we transfected the developed fusion proteins under the control of a tetracycline-regulated expression system into wild-type and ␣IIb␤3-expressing CHO cells and investigated their adhesive properties. Based on the results with the various CD7/␤3 fusion molecules, a CD7/VCAM-1 fusion molecule was designed containing the intracellular part of VCAM-1 and the extracellular and transmembrane part of CD7 in order to interfere with the cytoskeletal anchorage of VCAM-1 in a dominant negative manner. The functional consequences of transfection with the generated fusion protein were investigated in a CHO cell model, as well as in primary and immortalized endothelial cells (HUVEC and HMEC). The aim of our study was to investigate the feasibility of a gene therapy approach, specifically targeting the cytoskeletal anchorage of VCAM-1. Since monocyte recruitment into atherosclerotic plaques causes disease progression, blocking of monocyte adhesion to the vessel wall by local transfection of endothelial cells with a gene expressing a functional blocker of VCAM-1 may offer a novel therapeutic approach for the local treatment of atherosclerosis in coronary and carotid arteries. With the aim to prevent further progression of coronary atherosclerosis, local injection of an adenovirus containing a VCAM-1 inactivating gene into the coronary arteries could be performed in the cardiac catheter laboratory and may be feasible for human application. Local gene delivery by adenovirus vector systems has already been successfully employed in animal models

Materials and methods
Reagents and antibodies
Peripheral blood mononuclear cells and flow cytometry
Monocyte isolation from whole blood and flow cytometry were performed as described before [21] . (Fig. 3C) .
Inhibition of monocyte adhesion to VCAM-1 expressing CHO cells by CD7/VCAM-1
Based on the results obtained with the CD7(⌬215)␤3 chimera exhibiting strong dominant negative inhibition, we constructed a CD7/VCAM-1 chimera utilizing the same approach with a spatial separation of the VCAM-1 intracellular domain from the cell membrane (Fig. 1) (Fig. 4A) . Thus, CD7/VCAM-1 co-expression was able to inhibit VCAM-1-mediated monocyte adhesion. (Fig. 4G) . These results implicate a highly specific action of CD7/VCAM-1 on the native VCAM-1 receptor. Fig. 5A) . Fig. 5C) .
To further characterize the VCAM-1 monocyte interaction, we studied the effect of anti-VCAM-1 and anti-VLA-4 (CD49d/CD29) (both 10 g/ml for 15 min.) antibody treatment. After pre-incubation with anti-VCAM-1, the amount of adhering monocytes to double transfected (CD7/VCAM-1 and VCAM-1) CHO cells was reduced to control levels (Fig. 4B). We observed comparable results by blocking the VCAM-1 counter receptor VLA-4 on monocytes using an anti-CD49d antibody (Fig. 4C). Furthermore, we used cytochalasin D, an inhibitor of actin polymerization to interrupt the cytoskeletal organization. After doxycycline treatment (to suppress expression of CD7/VCAM-1), cytochalasin D reduced monocyte binding significantly (P < 0.001) (Fig. 4A). This indicates that cytoskeletal anchorage is necessary for the proper function of VCAM-1 and that CD7/VCAM-1 competes with VCAM-1 in its interaction with the actin cytoskeleton. The specificity of the CD7/VCAM-1 construct to inhibit VCAM-1 was assessed in CHO cells stably expressing either ICAM-1 or E-selectin. We found no effect of CD7/VCAM-1 transfection on ICAM-1-mediated monocyte adhesion, but treatment with cytochalasin D (Fig. 4D) as well as pre-incubation with a function blocking anti-ICAM-1-antibody (10 g/ml for 15 min.) significantly reduced monocyte adhesion (Fig. 4E). In addition, monocyte adhesion to CHO cells transfected with E-selectin was also not affected by co-transfection of CD7/VCAM-1, but a function blocking anti-E-selectin-antibody (10 g/ml for 15 min.) led to a significant reduction in the number of adhering monocytes (Fig. 4F). Treatment with cytochalasin D had no effect on E-selectin mediated monocyte adhesion, indicating monocyte binding to E-selectin is independent of cytoskeleton interaction
Inhibition of VCAM-1-mediated monocyte transmigration by CD7/VCAM-1
After observing the influence of the CD7/VCAM-1 chimera on monocyte adhesion, we studied the transmigration of monocytes
Fig. 3 Loss of cytoskeletal anchorage of ␣IIb␤3 upon CD7(⌬215)␤3 transfection. (A) Cells were transfected with ␣IIb␤3 and ␣IIb␤3 ϩ CD7(⌬215)␤3. Staining was performed with anti-␣IIb␤3-FITC, anti-phalloidin-TRITC and anti-CD7-FITC. ␣IIb␤3-expressing cells adhere and spread on fibrinogen and the interaction between integrin and cytoskeleton is manifested by the localization of ␣IIb␤3 in adhesion plaques and the organization of the actin cytoskeleton in stress fibres that span between adhesion plaques. After co-transfection with CD7(⌬215)␤3 ␣IIb␤3-expressing cells do not form adhesion plaques and do not form stress fibres. (B) Quantification of cell adhesion of transfected CHO cells on fibrinogen. Cells were transfected with ␣IIb␤3 and ␣IIb␤3 ϩ CD7(⌬215)␤3. Adhesion of ␣IIb␤3-transfected CHO cells were set to 100% adhesion. Binding was significantly reduced by co-transfection with CD7 (⌬215)␤3. Mean Ϯ S.D. for n ϭ 6 are given (***P < 0.001). (C) Quantification of cell adhesion of ␣IIb␤3-expressing CHO cells on fibrinogen under the influence of ReoPro (abciximab, 10 g/ml). Adhesion of ␣IIb␤3-transfected CHO cells was set to 100% adhesion. Binding was significantly reduced by ReoPro. Mean Ϯ S.D. for n ϭ 3 are given (***P < 0.001).
Fig. 4 VCAM-1, ICAM-1 and E-selectin mediated monocyte adhesion after treatment with CD7/VCAM-1, cytochalasin D, anti-VCAM-1, anti-VLA-4 and anti-E-selectin. Cells were transfected with either VCAM-1, ICAM-I, E-selectin, CD7/VCAM-1 or co-transfected. Expression of CD7/VCAM-1 was down regulated by doxycycline treatment. CD7/VCAM-1 effectively inhibits VCAM-1 but not ICAM-1 or E-selectin mediated monocyte adhesion. Adhesion was reduced after cytochalasin D treatment (50 ng/ml for 4 hrs) (A), anti-VCAM-1 (B) as well as anti-VLA-4 incubation (both 10 g/ml for 15 min.) (C). Adhesion was reduced in ICAM-I transfected cells after cytochalasin D treatment but not after CD7/VCAM-1 co-transfection (D) and after incubation with anti-ICAM-I antibodies (E). Adhesion was reduced in E-selectin transfected cells after incubation with anti-E-selectin antibodies (F), but not after CD7/VCAM-1 co-transfection or cytochalasin D treatment (G). Mean Ϯ S.D. for n ϭ 6 are given (***P < 0.001). through a cell layer of transfected CHO cells. We measured chemotaxis using a 24-well chemotaxis chamber containing an insert filter with monocytes plated onto the upper chamber. More monocytes were able to migrate through VCAM-1 expressing CHO cells compared with control CHO cells and CHO cells expressing CD7/VCAM-1 (Fig. 5A). Co-expression of CD7/VCAM-1 and VCAM-1 led to a significant reduction of migration to levels observed with the CHO control cells and suppression of CD7/VCAM-1 expression by doxycycline treatment significantly increased monocyte transmigration. Thus, VCAM-1 significantly contributes to monocyte transmigration, which is inhibitable by the newly developed approach targeting the cytoskeletal anchorage of VCAM-1 (
Transmigration was further characterized by antibody pre-incubation to block monocyte-to-cell interaction. Anti-VCAM-1 incubated double transfected CHO cells showed less monocyte migration compared to non-treated double transfected cells. Suppression of CD7/VCAM-1 expression restored transmigration,
Fig. 5 VCAM-1 and ICAM-1 mediated monocyte migration after treatment with CD7/VCAM-1, cytochalasin D and anti-VCAM-1. Cells were transfected with either VCAM-1, ICAM-I, CD7/VCAM-1 or co-transfected. Expression of CD7/VCAM-1 was down regulated by doxycycline treatment. Monocyte migration through VCAM-1-expressing CHO cells was inhibited by CD7/VCAM-1 (A), anti-VCAM-1 (B) and after cytochalasin D treatment (C). Migration of monocytes through ICAM-1-expressing CHO cells was not inhibited by transfection with CD7/VCAM-1, but cytoskeletal anchorage was essential for ICAM-1-mediated migration (D). Mean Ϯ S.D. for n ϭ 6 are given (***P < 0.001). demonstrating a VCAM-1-mediated migration of monocytes (Fig. 5B). Interruption of cytoskeletal anchorage with cytochalasin D had the same effect as co-transfection of CD7/VCAM-1 (
Involvement of ICAM-1 in monocyte transmigration has been reported [23] . Cytochalasin (Fig. 5D ). (Fig. 6A) . Vector-only transfected control cells showed similar levels of adhesion as non-transfected cells. Co-expression of CD7/VCAM-1 reduced the level of monocyte adhesion from inflammatory levels to non-inflammatory levels (Fig. 6A) (Fig. 6C compared  to 6D ). However, following IL-1␤ stimulation, CD7/VCAM-1 transfection also significantly inhibited monocyte rolling.
Adenoviral transfer of CD7/VCAM-1 to HUVECs inhibits monocyte adhesion and attenuates monocyte transmigration
Finally, we tested the effect of CD7/VCAM-1 transfection directly in human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMEC). With HUVECs, more adherent monocytes were detected with IL-1␤ stimulated cells compared to non-stimulated HUVECs. IL-1␤ rapidly up regulates VCAM-1 and E-selection in human endothelial cells (data not shown). Transfection with CD7/VCAM-1 resulted in a significant reduction of adhesion for non-stimulated and stimulated cells
Discussion
Local treatment of rupture-prone atherosclerotic plaques and prevention of atherosclerosis are major challenges in cardiovascular medicine. Adhesion receptors play a crucial role in the development of atherosclerosis by mediating the required cell-cell interactions leading to the establishment of atherosclerotic plaques. Cytoskeletal anchorage is necessary for the function of many adhesion receptors including the integrin ␣IIb␤3, for which proper anchorage is a prerequisite for its multiple functions [13, 16] . The integrin cytoplasmic tails in general and the cytoplasmic domain of the integrin ␤-subunits in particular are crucial for the interaction with the cell's cytoskeleton. The interruption of integrin ␤-subunits' cytoskeletal anchorage results in the loss of adhesive function [20, 24] . Therefore, we postulated that ␤3-chimeras, with an inert extracellular component, may compete with the native receptors' cytoskeletal anchorage, thereby interfering with receptor clustering, signaling and adhesive properties of the receptor.
Our concept of competitive and potentially dominant negative inhibition of cytoskeletal anchorage was first established in an integrin
␣IIb␤3-based CHO cell model (Figs 2 and 3) . [26, 27] and on B-cells or myeloid precursor cells before they enter the thymus during embryonic development [28, 29] . It is also used as a diagnostic marker for lymphatic T cell leukemia [30] and has recently been used for the targeting of soluble Fas-Ligand (sFasL) to CD7-expressing cells via a CD7 specific single-chain antibody as a novel therapeutic approach for acute T cell leukemia [31] . Depending on the fusion site between CD7 and ␤3 two mechanism of inhibition seem to occur in our CHO cell model (Figs 1 and 2) . The construct CD7(⌬215)␤3 (Fig. 1) The blockade of VCAM-1 appears to be a promising approach to reduce vascular damage [34] . There is strong evidence that VCAM-1 is one of the major players in monocyte recruitment [8, 35] and it has been shown to enhance monocyte and macrophage adhesion in rats [36] , mice [37] and rabbits [38] . Furthermore, blockade of VCAM-1 with monoclonal antibodies has been shown to inhibit adhesion and transmigration of a human monocyte cell line to human aortic endothelial cells [39] . Anti-oxidative drugs have been found to repress ICAM-1 and VCAM-1 [40] . Direct blockade of the VCAM-1 counter receptor VLA-4 with different specific peptides has been observed to successfully attenuate monocyte migration and inflammatory reactions [41] . Blockade of VCAM-1 in hypercholesterolaemic mice has been shown to result in reduced neointima formation due to the inhibition of monocyte migration [42, 43] (Fig. 4A-C) and migration (Fig. 5A-C [48] , our studies confirm that E-selectin alone can also mediate monocyte adhesion but not migration (Fig. 4F-G) , whereas ICAM-1 is able to mediate both adhesion (Fig. 4D-E) and migration (Fig. 5D) [50] (Figs 4D and 5D) , whereas monocyte adhesion mediated by E-selectin occurs without cytoskeletal anchorage [51] (Fig. 4G) 
The extracellular part of CD7, a small membrane protein (40 kD) of the Ig-superfamily [25] was used for the construction of CD7/␤3-chimeras as it is generally considered as an inert extracellular marker. CD7 is found on mature T cells, natural killer cells
